Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 6:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 270 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hepatic Failure Clear all

Conditions: End Stage Liver Disease
Interventions: Enteric-coated Mycophenolate Sodium; Drug
Lead sponsor: R. Mark Ghobrial, MD; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cirrhosis, Hepatic Encephalopathy, Fatigue, Depression
Interventions: Not listed
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 70 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Neoplasm Metastases, Hepatic Insufficiency
Interventions: Trabectedin, Dexamethasone; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 6
States / cities: Scottsdale, Arizona • Detroit, Michigan • New York, New York + 3 more

Conditions: Liver Diseases, Hepatocellular Cancer, End Stage Liver Disease, Hepatitis C, Liver Cirrhosis
Interventions: Not listed
Lead sponsor: Arbor Research Collaborative for Health; Other
Eligibility: 18 Years and older
Enrollment: 1,871 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 8
States / cities: San Francisco, California • Aurora, Colorado • Chicago, Illinois + 5 more

Conditions: Hepatitis C, Cirrhosis, Portal Hypertension, With or Without Liver Decompensation
Interventions: SOF, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 4
States / cities: Aurora, Colorado • Boston, Massachusetts • Rochester, Minnesota + 1 more

Conditions: Cirrhosis
Interventions: Lactulose; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Obesity, Hepatic Insufficiency
Interventions: CP-945,598; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: End Stage Liver Disease
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2030
U.S. locations: 12
States / cities: Little Rock, Arkansas • Loma Linda, California • San Francisco, California + 9 more

Conditions: Cirrhosis
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 21 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Cirrhosis, Hepatic Encephalopathy, Minimal Hepatic Encephalopathy, Covert Hepatic Encephalopathy
Interventions: 25% IV albumin, Placebo; Biological · Other
Lead sponsor: Hunter Holmes Mcguire Veteran Affairs Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Hepatitis
Interventions: Emapalumab; Drug
Lead sponsor: Children's Healthcare of Atlanta; Other
Eligibility: 1 Year to 30 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Hepatic Encephalopathy, Liver Cirrhosis
Interventions: Flumazenil, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 99 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Hepatic Encephalopathy, Ascites, Liver Diseases, Cirrhosis
Interventions: Meal delivery, Standard pamphlet with Dietary Advice; Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Hepatic Encephalopathy
Interventions: AST-120, lactulose; Drug
Lead sponsor: Ocera Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 17
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 11 more

Conditions: End Stage Liver Failure
Interventions: N-acetylcysteine; Drug
Lead sponsor: Ibtesam Hilmi; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Congestive Heart Failure, Diabetes, Cardiovascular Disease
Interventions: Tailored Healthmedia programs on EHR Patient Portal; Procedure
Lead sponsor: Robert Wood Johnson Foundation; Other
Eligibility: 18 Years and older
Enrollment: 6,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Danville, Pennsylvania

Conditions: Hepatic Encephalopathy
Interventions: Rifaximin; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Cerebrovascular Accident, Cancer, Coronary Arteriosclerosis, Heart Failure, Congestive, Diabetes Mellitus, Acquired Immunodeficiency Syndrome, Failure to Thrive, Pulmonary Disease, Chronic Obstructive, Dementia, Kidney Failure, Chronic, Pneumonia, Liver Failure, Renal Failure, Respiratory Failure, Stroke
Interventions: Multidisciplinary palliative care team met with patient; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Acute Episode of Overt Hepatic Encephalopathy, Hepatic Encephalopathy
Interventions: ornithine phenylacetate, placebo intravenous infusion; Drug
Lead sponsor: Ocera Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 49
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Coronado, California + 29 more

Conditions: Hepatic Encephalopathy
Interventions: Ensure Enlive, Standard Of Care; Dietary Supplement · Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Mild Hepatic Encephalopathy
Interventions: AST-120; Drug
Lead sponsor: Ocera Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 38
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 29 more

Conditions: Hepatic Encephalopathy
Interventions: Rifaximin SSD, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 524 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 139
States / cities: Dothan, Alabama • Chandler, Arizona • Peoria, Arizona + 103 more

Conditions: End Stage Liver Disease
Interventions: Leukapheresis; Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hepatic Impairment
Interventions: Cenicriviroc; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Search by objective public record fields.

Myfortic, Prograf, and Corticosteroids in de Novo Liver Transplantation

Factors Associated With End Stage Liver Disease

A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction

Adult-to-Adult Living Donor Transplant Cohort Study

Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation

A Trial to Improve Quality of Life in People With Cirrhosis

Study Examining The Effect Of Hepatic Impairment On Safety, Toleration And How The Body Processes An Experimental Drug

Functional Assessment in Liver Transplantation

Assessment of Endothelial Function, Apolipoproteins and Adiponectin

HEAL STUDY (Hepatic Encephalopathy and Albumin Study)

Severe Hepatitis Intervention With Emapalumab for Liver Disease

Treatment of Hepatic Encephalopathy With Flumazenil and Change in Cortical GABA Levels in MRS

Tackling 30-day Readmissions in Patients With Cirrhosis: The SALTYFOOD Trial

Safety and Efficacy of AST-120 Compared to Lactulose in Patients With Hepatic Encephalopathy

N-acetylcysteine in Liver Transplantation

Does Access to an EHR Patient Portal Influence Chronic Disease Outcomes?

The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy.

Multidisciplinary Inpatient Palliative Care Intervention

Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)

Late Evening and Early Morning Protein Supplement to Reduce Readmissions for Hepatic Encephalopathy

AST-120 Used to Treat Mild Hepatic Encephalopathy

Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis

Procurement of Leukapheresis Products From End Stage Liver Disease (ESLD) Patients for Immunological Studies

Impact of Severe Hepatic Impairment on Pharmacokinetics of Cenicriviroc and Its Metabolites